Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.4B | $26.1B | $22.1B | $22.4B | $24.7B | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B |
| Revenue growth | — | -14.1% | -15.2% | 1.5% | 10.0% | 10.6% | -0.1% | -0.6% | 6.0% | 2.4% |
| Operating income | $17.6B | $14.1B | $8.20B | $4.29B | $4.07B | $9.92B | $7.33B | $7.61B | $1.66B | $10.0B |
| Operating margin | 58.0% | 54.1% | 37.1% | 19.1% | 16.5% | 36.3% | 26.9% | 28.0% | 5.8% | 34.0% |
| Net income | $13.5B | $4.63B | $5.46B | $5.39B | $123M | $6.22B | $4.59B | $5.67B | $480M | $8.51B |
| Net margin | 44.4% | 17.7% | 24.7% | 24.0% | 0.5% | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% |
| EPS (diluted) | $9.94 | $3.51 | $4.17 | $4.22 | $0.10 | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $17.0B | $11.9B | $8.40B | $9.14B | $8.17B | $11.4B | $9.07B | $8.01B | $10.8B | $10.0B |
| Capital expenditures | $748M | $590M | $924M | $825M | $650M | $579M | $728M | $585M | $523M | $563M |
| Free cash flow | $16.3B | $11.3B | $7.48B | $8.32B | $7.52B | $10.8B | $8.34B | $7.42B | $10.3B | $9.46B |
| Share buybacks | $11.0B | $954M | $2.90B | $1.75B | $1.58B | $546M | $1.40B | $1.00B | $1.15B | $1.92B |
| Dividends paid | $2.46B | $2.73B | $2.97B | $3.22B | $3.45B | $3.60B | $3.71B | $3.81B | $3.92B | $4.00B |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $8.23B | $7.59B | $17.9B | $11.6B | $6.00B | $5.34B | $5.41B | $6.08B | $9.99B | $7.56B |
| Total assets | $57.0B | $70.3B | $63.7B | $61.6B | $68.4B | $68.0B | $63.2B | $62.1B | $59.0B | $59.0B |
| Long-term debt | $26.3B | $30.8B | $24.6B | $22.1B | $28.6B | $25.2B | $23.0B | $23.2B | $24.9B | $22.1B |
| Shareholders' equity | $18.9B | $20.4B | $21.4B | $22.5B | $18.2B | $21.1B | $21.2B | $22.8B | $19.3B | $22.7B |
| Retained earnings | $18.2B | $19.0B | $19.0B | $19.4B | $14.4B | $16.3B | $15.7B | $16.3B | $11.5B | $13.7B |
| Shares (wtd avg diluted) | 1.36B | 1.32B | 1.31B | 1.28B | 1.26B | 1.26B | 1.26B | 1.26B | 1.25B | 1.25B |
Every figure is extracted from GILEAD SCIENCES, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.